Revenue Update on Tobira Therapeutics Inc(NASDAQ:TBRA)

Tobira Therapeutics Inc(NASDAQ:TBRA) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $1.06M. Analysts estimated a revenue of $50.00K. Earnings per share were $-0.71. Analysts had estimated an EPS of $-0.63.

In a different note, Cantor Fitzgerald said it Initiates Coverage on Tobira Therapeutics Inc, according to a research note issued on Jul 6, 2016. The shares have been rated ‘Buy’ by the firm.

Tobira Therapeutics Inc (TBRA) shares turned negative on Wednesdays trading session with the shares closing down -0.17 points or -3.55% at a volume of 4,55,077. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.83. The peak price level was also seen at $4.83 while the days lowest was $4.45. Finally the shares closed at $4.62. The 52-week high of the shares is $14.53 while the 52-week low is $3.76. According to the latest information available, the market cap of the company is $87 M.

Several Insider Transactions has been reported to the SEC. On Jul 13, 2016, A/s Novo (10% owner) sold 59,067 shares at $12.06 per share price.

Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *